Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Culine, Stéphane
Harter, Valentin
Krucker, Clémentine
Gravis, Gwénaëlle
Fléchon, Aude
Chevreau, Christine
Mahammedi, Hakim
Laguerre, Brigitte
Guillot, Aline
Joly, Florence
Fontugne, Jacqueline
Allory, Yves
Pfister, Christian

January 2023

International audienceNeoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy ...

A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer

Hussain, S. A.
Palmer, D. H.
Lloyd, B.
Collins, S. I.
Barton, D.
Ansari, J.
James, Nicholas D.

January 2012

The aim of this study was to investigate the outcome of patients with muscle-invasive bladder cancer...

A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder

Challapalli, Amarnath
Masson, Susan
White, Paul
Dailami, Narges
Pearson, Sylvia
Rowe, Edward
Koupparis, Anthony
Oxley, Jon
Abdelaziz, Ahmed
Ash-Miles, Janice
Bravo, Alicia
Foulstone, Emily
Perks, Claire
Holly, Jeff
Persad, Raj
Bahl, Amit

August 2021

Introduction: Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invas...

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Culine, Stéphane
Harter, Valentin
Gravis, Gwenaelle
Fléchon, Aude
Chevreau, Christine
Mahammedi, Hakim
Laguerre, Brigitte
Guillot, Aline
Joly, Florence
Abadie-Lacourtoisie, Sophie
Geoffrois, Lionnel
Di Fiore, Frederic
Roubaud, Guilhem
Barthélémy, Philippe
Voog, Eric
Emambux, Sheik
Serrate, Camille
Saldana, Carolina
Hon, Thierry Nguyen Tan
Loriot, Yohann
Eymard, Jean-Christophe
Huillard, Olivier
Rolland, Frédéric
Houédé, Nadine
Spano, Jean-Philippe
Demery, Mounira El
Vieillot, Sabine
L'Haridon, Tifenn
Hilgers, Werner
Allory, Yves
Pfister, Christian

December 2021

International audienceBackground: Cisplatin-based combination chemotherapy before surgery is the sta...

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Culine, Stéphane
Harter, Valentin
Gravis, Gwenaelle
Fléchon, Aude
Chevreau, Christine
Mahammedi, Hakim
Laguerre, Brigitte
Guillot, Aline
Joly, Florence
Abadie-Lacourtoisie, Sophie
Geoffrois, Lionnel
Di Fiore, Frederic
Roubaud, Guilhem
Barthélémy, Philippe
Voog, Eric
Emambux, Sheik
Serrate, Camille
Saldana, Carolina
Hon, Thierry Nguyen Tan
Loriot, Yohann
Eymard, Jean-Christophe
Huillard, Olivier
Rolland, Frédéric
Houédé, Nadine
Spano, Jean-Philippe
Demery, Mounira El
Vieillot, Sabine
L'Haridon, Tifenn
Hilgers, Werner
Allory, Yves
Pfister, Christian

December 2021

International audienceBackground: Cisplatin-based combination chemotherapy before surgery is the sta...

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Culine, Stéphane
Harter, Valentin
Gravis, Gwenaelle
Fléchon, Aude
Chevreau, Christine
Mahammedi, Hakim
Laguerre, Brigitte
Guillot, Aline
Joly, Florence
Abadie-Lacourtoisie, Sophie
Geoffrois, Lionnel
Di Fiore, Frederic
Roubaud, Guilhem
Barthélémy, Philippe
Voog, Eric
Emambux, Sheik
Serrate, Camille
Saldana, Carolina
Hon, Thierry Nguyen Tan
Loriot, yohann
Eymard, Jean-Christophe
Huillard, Olivier
Rolland, Frédéric
Houédé, Nadine
Spano, Jean-Philippe
Demery, Mounira El
Vieillot, Sabine
L'Haridon, Tifenn
Hilgers, Werner
Allory, yves
Pfister, Christian

December 2021

International audienceBackground: Cisplatin-based combination chemotherapy before surgery is the sta...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Culine, Stéphane
Harter, Valentin
Krucker, Clémentine
Gravis, Gwénaëlle
Fléchon, Aude
Chevreau, Christine
Mahammedi, Hakim
Laguerre, Brigitte
Guillot, Aline
Joly, Florence
Fontugne, Jacqueline
Allory, Yves
Pfister, Christian

January 2023

International audienceNeoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy ...

A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer

Hussain, S. A.
Palmer, D. H.
Lloyd, B.
Collins, S. I.
Barton, D.
Ansari, J.
James, Nicholas D.

January 2012

The aim of this study was to investigate the outcome of patients with muscle-invasive bladder cancer...

A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder

Challapalli, Amarnath
Masson, Susan
White, Paul
Dailami, Narges
Pearson, Sylvia
Rowe, Edward
Koupparis, Anthony
Oxley, Jon
Abdelaziz, Ahmed
Ash-Miles, Janice
Bravo, Alicia
Foulstone, Emily
Perks, Claire
Holly, Jeff
Persad, Raj
Bahl, Amit

August 2021

Introduction: Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invas...

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Culine, Stéphane
Harter, Valentin
Gravis, Gwenaelle
Fléchon, Aude
Chevreau, Christine
Mahammedi, Hakim
Laguerre, Brigitte
Guillot, Aline
Joly, Florence
Abadie-Lacourtoisie, Sophie
Geoffrois, Lionnel
Di Fiore, Frederic
Roubaud, Guilhem
Barthélémy, Philippe
Voog, Eric
Emambux, Sheik
Serrate, Camille
Saldana, Carolina
Hon, Thierry Nguyen Tan
Loriot, Yohann
Eymard, Jean-Christophe
Huillard, Olivier
Rolland, Frédéric
Houédé, Nadine
Spano, Jean-Philippe
Demery, Mounira El
Vieillot, Sabine
L'Haridon, Tifenn
Hilgers, Werner
Allory, Yves
Pfister, Christian

December 2021

International audienceBackground: Cisplatin-based combination chemotherapy before surgery is the sta...

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Culine, Stéphane
Harter, Valentin
Gravis, Gwenaelle
Fléchon, Aude
Chevreau, Christine
Mahammedi, Hakim
Laguerre, Brigitte
Guillot, Aline
Joly, Florence
Abadie-Lacourtoisie, Sophie
Geoffrois, Lionnel
Di Fiore, Frederic
Roubaud, Guilhem
Barthélémy, Philippe
Voog, Eric
Emambux, Sheik
Serrate, Camille
Saldana, Carolina
Hon, Thierry Nguyen Tan
Loriot, Yohann
Eymard, Jean-Christophe
Huillard, Olivier
Rolland, Frédéric
Houédé, Nadine
Spano, Jean-Philippe
Demery, Mounira El
Vieillot, Sabine
L'Haridon, Tifenn
Hilgers, Werner
Allory, Yves
Pfister, Christian

December 2021

International audienceBackground: Cisplatin-based combination chemotherapy before surgery is the sta...

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Culine, Stéphane
Harter, Valentin
Gravis, Gwenaelle
Fléchon, Aude
Chevreau, Christine
Mahammedi, Hakim
Laguerre, Brigitte
Guillot, Aline
Joly, Florence
Abadie-Lacourtoisie, Sophie
Geoffrois, Lionnel
Di Fiore, Frederic
Roubaud, Guilhem
Barthélémy, Philippe
Voog, Eric
Emambux, Sheik
Serrate, Camille
Saldana, Carolina
Hon, Thierry Nguyen Tan
Loriot, yohann
Eymard, Jean-Christophe
Huillard, Olivier
Rolland, Frédéric
Houédé, Nadine
Spano, Jean-Philippe
Demery, Mounira El
Vieillot, Sabine
L'Haridon, Tifenn
Hilgers, Werner
Allory, yves
Pfister, Christian

December 2021

International audienceBackground: Cisplatin-based combination chemotherapy before surgery is the sta...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Pfister, Christian
Harter, Valentin
Allory, Yves
Radvanyi, François
Culine, Stéphane
Grawis, G.
Pignot, G.
Flechon, A.
Fendler, J.P.
Chevreau, C.
Soulié, M.
Mahammedi, H.
Guy, L.
Laguerre, B.
Verhoest, G.
Guillot, A.
Mottet, N.
Joly, F.
Doerfler, A.
Abadie-Lacourtoisie, S.
Azzouzi, A.R.
Mongiat, P.
Geoffrois, L.
Eschwege, P.
Di Fiore, F.
Roubaud, G.
Hoepffner, J.L.
Barthelemy, P.
Lang, H.
Voog, E.
Mandron, E.
Tourani, J.M.
Serrrate, C.
Colau, A.
Saldana, C.
de La Taille, A.
Nguyen, T.
Kleinclauss, F.
Loriot, Y.
Irani, J.
Eymard, J.C.
Larre, S.
Huillard, O.
Zerbib, M.
Rolland, F.
Rigaud, J.
Houédé, N.
Droupy, S.
Malouf, G.
Roupret, M.
El Demery, M.
Legon, C.
Vieillot, S.
Letang, N.
Lharidon, T.
Gaschignard, N.
Hilgers, W.
Davin, J.L.

March 2020

International audienceThe main objective of the French GETUG/AFU V05 VESPER randomized phase III stu...

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Culine, Stéphane
Harter, Valentin
Krucker, Clémentine
Gravis, Gwénaëlle
Fléchon, Aude
Chevreau, Christine
Mahammedi, Hakim
Laguerre, Brigitte
Guillot, Aline
Joly, Florence
Fontugne, Jacqueline
Allory, Yves
Pfister, Christian

January 2023

International audienceNeoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy ...

A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer

Hussain, S. A.
Palmer, D. H.
Lloyd, B.
Collins, S. I.
Barton, D.
Ansari, J.
James, Nicholas D.

January 2012

The aim of this study was to investigate the outcome of patients with muscle-invasive bladder cancer...

A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder

Challapalli, Amarnath
Masson, Susan
White, Paul
Dailami, Narges
Pearson, Sylvia
Rowe, Edward
Koupparis, Anthony
Oxley, Jon
Abdelaziz, Ahmed
Ash-Miles, Janice
Bravo, Alicia
Foulstone, Emily
Perks, Claire
Holly, Jeff
Persad, Raj
Bahl, Amit

August 2021

Introduction: Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invas...

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Abstract

Extracted data

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Abstract

Extracted data

Topics

Related items

Related items

Topics